Article Figures & Data
Figures
- Figure 1.
Four-year crude retention rates of anti-TNF therapy in patients with PsA by drug. TNF: tumor necrosis factor; PsA: psoriatic arthritis.
- Figure 2.
Percentages of patients taking concomitant prednisone (steroids) or disease-modifying antirheumatic drugs (DMARD) at baseline and at different subsequent timepoints. After 24 months, a significant reduction of glucocorticoid and DMARD intake was observed (p values are referred to baseline).
- Figure 3.
Four-year values (mean ± 1 SD). A. 68 tender joint count (TJC), 66 swollen joint count (SJC), 28-joint disease Activity Scores (DAS28), Health Assessment Questionnaire (HAQ). B. Visual analog scale (VAS) of pain, patient global assessment of disease activity (PtGA). A rapid decrease is shown at 6 months that was sustained up to 48 months.
Tables
- Table 1.
Baseline demographics of 420 patients with PsA, subdivided by anti-TNF drug. All data are median (range) unless otherwise indicated.
All, n = 420 ADA, n = 139 ETN, n = 197 IFX, n = 84 p Age, yrs 50 (16–81) 46 (18–72) 51 (16–81) 50 (16–77) 0.24 Duration, yrs 4 (0.8–39) 3.3 (0.8–37) 3.0 (0.3–35) 4.5 (0.4–39) 0.32 ESR, mm/h 16 (2–97) 13 (2–90) 16 (2–97) 22 (2–90) 0.03 CRP, mg/dl 0.4 (0.1–14) 0.3 (0.1–12) 0.4 (0.1–14) 0.5 (0.1–10) 0.04 68-TJC 7 (1–59) 7 (1–57) 7 (1–59) 8 (1–47) 0.70 66-SJC 1 (0–42) 1 (0–42) 1 (1–36) 2 (1–33) 0.84 DAS28 4.3 (1.4–8.6) 4.1 (1.4–7.1) 4.2 (1.6–8.6) 4.8 (1.8–8.4) 0.02 HAQ 1.12 (0.1–3.0) 1.12 (0.1–2.75) 1.12 (0.1–3.0) 1.25 (0.1–3.0) 0.81 VAS-Pain 70 (10–100) 60 (10–100) 70 (10–100) 70 (10–100) 0.55 PtGA 70 (10–100) 60 (10–100) 70 (10–100) 70 (10–100) 0.06 PASI 1.2 (0–47) 1.2 (0–47) 0.8 (0–18) 6.3 (0–14) 0.01 Predn (mg/day) 5.0 (2.5–25) 5.0 (2.5–10) 5.0 (2.5–15) 5.0 (2.5–25) 0.08 Female, n (%) 257 (61) 85 (61) 122 (62) 50 (60) 0.91 CRP > 1, n (%) 110 (29) 28 (23) 53 (28) 29 (37) 0.14 Predn, n (%) 204 (50) 67 (50) 102 (52) 35 (43) 0.38 DMARD, n (%) 245 (60) 87 (64) 106 (54) 52 (64) 0.11 PsA: psoriatic arthritis; TNF: tumor necrosis factor; ADA: adalimumab; ETN: etanercept; IFX: infliximab; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: 28-joint Disease Activity Score; 68-TJC: 68 joint tender joint count; 66-SJC: 66 joint swollen joint count; VAS: visual analog scale; HAQ: Health Assessment Questionnaire; PtGA: patient’s global assessment of disease activity; PASI: Psoriasis Area and Severity Index; DMARD: disease-modifying antirheumatic drugs; Predn: prednisone.
- Table 2.
HR estimates of anti-TNF discontinuation at 4 years by univariate and multivariate Cox regression analysis.
Univariate Multivariate Baseline covariates HR 95% CI p HR 95% CI p Age 0.99 0.98–1.00 0.79 0.99 0.98–1.01 0.88 Sex, female/male 1.75 1.20–2.36 0.001 2.02 1.28–3.20 0.002 Disease duration 0.97 0.94–1.00 0.64 0.96 0.93–0.99 0.02 Oligo/polyarticular 0.78 0.58–1.05 0.11 1.20 0.73–1.99 0.45 CRP, ≥ 1 mg/dl / < 1 mg/dl 0.93 0.67–1.29 0.67 1.29 0.83–1.89 0.25 68-tender joint count 1.01 1.00–1.02 0.04 1.00 0.98–1.02 0.71 66-swollen joint count 1.00 0.97–1.03 0.74 0.99 0.95–1.03 0.75 HAQ 1.20 0.97–1.48 0.79 1.16 0.85–1.59 0.32 Calendar year 1.02 0.97–1.07 0.36 1.06 0.99–1.13 0.94 DMARD, yes/no 1.03 0.77–1.38 0.80 0.89 0.61–1.30 0.65 Prednisone, yes/no 1.00 0.76–1.33 0.96 1.08 0.74–1.58 0.65 Drug Infliximab 1 Adalimumab 1.10 0.77–1.58 0.58 0.93 0.56–1.54 0.79 Etanercept 0.68 0.48–0.98 0.04 0.57 0.34–0.93 0.02 TNF: tumor necrosis factor; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; DMARD: disease-modifying antirheumatic drug.
- Table 3.
Clinical outcomes of anti-TNF treatment up to 4 years in patients with psoriatic arthritis. Frequencies of patients achieving a “good” EULAR response or HAQ improvement ≥ 0.5 from baseline (DHAQ) are given. Adalimumab (ADA), etanercept (ETN), and infliximab (IFX) are compared by chi-squared test. Except for p values, data are percentages.
“Good” EULAR Response ΔHAQ ≥ 0.5 ADA ETN IFX p ADA ETN IFX p 6 mos 59 70 71 0.13 49 57 46 0.12 1 yr 59 73 78 0.02 55 65 75 0.04 2 yrs 70 74 85 0.17 63 66 69 0.75 3 yrs 67 76 85 0.04 58 62 57 0.62 4 yrs 61 79 83 0.04 61 56 61 0.79 TNF: tumor necrosis factor; EULAR: European League Against Rheumatism; HAQ: Health Assessment Questionnaire.
